Author(s)

Eric W. Cerrati¹, Teresa M. O^2*, David Binetter², Yelena Bernstein², Milton Waner²

¹Department of Otolaryngology, New York University, New York, USA.
²Vascular Birthmark Institute of New York, Lenox Hill and Manhattan Eye, Ear and Throat Hospitals, New York, USA.

Purpose: Bleomycin is an antibiotic medication that inhibits the synthesis of DNA, RNA, and proteins and is now used in a variety of medical conditions including vascular anomalies. The aim of this study was to evaluate the clinical efficacy of transmucosal intralesional injection of bleomycin in the management of tongue lymphatic malformations. Method: A single institutional case series was presented on patients with recalcitrant lymphatic malformations of the tongue who were treated with bleomycin. Age at the time of injection, gender, number of treatments, amount of bleomycin injected per session, post-injection complications, pre- and post-injection symptoms, and anatomic extent of the lymphatic malformation were all recorded and analyzed. Results: Five patients received transmucosal bleomycin and were followed over a 10-month period. The patients included 4 females and 1 male, aged from 3.25 to 36 years (average 13.52 years). Four patients had one treatment while 1 required two treatments. A total of 1 to 6 units were injected per session. Overall reduction in size of the lymphatic malformation and improvement in all symptoms were observed in the patients by day 14. Average follow-up was 9 to 12 months. Conclusion: Intralesional injection of bleomycin is an effective treatment modality in patients with lymphatic malformations of the tongue.

Bleomycin, Sclerotherapy, Lymphatic Malformation, Tongue

Cerrati, E. , O., T. M. , Binetter, D. , Bernstein, Y. and Waner, M. (2015) Transmucosal Bleomycin for Tongue Lymphatic Malformations. International Journal of Otolaryngology and Head & Neck Surgery, 4, 81-85. doi: 10.4236/ijohns.2015.42015.